tm logo
ALYGLO
Live/Pending
FOURTH EXTENSION - GRANTED

granted

on 14 Feb 2024

Last Applicant/ Owned by

107, Ihyeon-ro 30beon-gil, Giheung-gu,

Yongin-si, Gyeonggi-do

KR

16924

Serial Number

90160114 filed on 04th Sep 2020

Registration Number

N/A

Correspondent Address

KWANG YUP CHAE

Hauptman Ham, LLP

2318 Mill Road

Suite 1400

Alexandria,VA 22314

Filing Basis

1. intent to use

2. intent to use current

Disclaimer

NO DATA

ALYGLO

Blood plasma derivatives for medical purposes, namely, immune globulins including Rh immune globulin; Immunoglobulin preparations, namely, pharmaceutical immunoglobulin preparations for diagnosis of primary humoral immunodeficiency, common variable immune deficiency, X-linked agammaglobulinemia (XLA), hyper immunoglobulin M syndromes, Wiskott Aldrich syndrome, severe combined immune deficiency (SCRead More

Classification Information


Class [005]
Pharmaceutical Products


Blood plasma derivatives for medical purposes, namely, immune globulins including Rh immune globulin; Immunoglobulin preparations, namely, pharmaceutical immunoglobulin preparations for diagnosis of primary humoral immunodeficiency, common variable immune deficiency, X-linked agammaglobulinemia (XLA), hyper immunoglobulin M syndromes, Wiskott Aldrich syndrome, severe combined immune deficiency (SCID), agammaglobulinemia, hypogammaglobulinemia, inflammatory diseases, immunological disorders, bacterial infections, acute serious bacterial infection, chronic inflammatory demyelinating polyneuropathy (CIDP) and immune thrombocytopenic purpura (ITP), for preventing primary humoral immunodeficiency, Kawasaki disease, Guillain-Barre syndrome, common variable immune deficiency, X-linked agammaglobulinemia (XLA), hyper immunoglobulin M syndromes, Wiskott Aldrich syndrome and severe combined immune deficiency (SCID), agammaglobulinemia, hypogammaglobulinemia, cardiovascular disease, inflammatory diseases, immunological disorders, bacterial infections, acute serious bacterial infection, chronic inflammatory demyelinating polyneuropathy (CIDP) and immune thrombocytopenic purpura (ITP), and for treatment of primary humoral immunodeficiency, Kawasaki disease, Guillain-Barre syndrome, common variable immune deficiency, X-linked agammaglobulinemia (XLA), hyper immunoglobulin M syndromes, Wiskott Aldrich Syndrome and severe combined immune deficiency (SCID), agammaglobulinemia, hypogammaglobulinemia, cardiovascular disease, inflammatory diseases, immunological disorders, bacterial infections, acute serious bacterial infection, chronic inflammatory demyelinating polyneuropathy (CIDP) and immune thrombocytopenic purpura (ITP); all the foregoing for patient treatment by injection or in liquid form by health professional

Mark Details


Serial Number

No 90160114

Mark Type

No Service/Collective Mark

Attorney Docket Number

No 5734-0284TM

44D Filed

No

44D Current

No

44E filed

No

44E Current

No

66A Filed

No

66A Current

No

Current Basis

No

No Basis

No

Legal History


Show more

Status DateAction Taken
03rd Apr 2024ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
15th Feb 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
14th Feb 2024SOU TEAS EXTENSION RECEIVED
14th Feb 2024SOU EXTENSION 4 FILED
14th Feb 2024SOU EXTENSION 4 GRANTED
30th Aug 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
28th Aug 2023SOU TEAS EXTENSION RECEIVED
28th Aug 2023SOU EXTENSION 3 FILED
28th Aug 2023SOU EXTENSION 3 GRANTED
24th Feb 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED